Fresenius Medical Care AG (FMS)
- Previous Close
25.62 - Open
27.41 - Bid 28.54 x 1200
- Ask 28.59 x 1000
- Day's Range
26.97 - 27.65 - 52 Week Range
17.93 - 27.65 - Volume
676,269 - Avg. Volume
381,113 - Market Cap (intraday)
16.085B - Beta (5Y Monthly) --
- PE Ratio (TTM)
26.36 - EPS (TTM)
1.04 - Earnings Date Aug 5, 2025
- Forward Dividend & Yield 0.64 (2.35%)
- Ex-Dividend Date May 17, 2024
- 1y Target Est
27.01
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, physician nephrology, ambulant treatment, and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
www.freseniusmedicalcare.com111,513
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: FMS
View More
Performance Overview: FMS
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FMS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FMS
View MoreValuation Measures
Market Cap
16.08B
Enterprise Value
26.87B
Trailing P/E
22.95
Forward P/E
13.05
PEG Ratio (5yr expected)
0.95
Price/Sales (ttm)
0.73
Price/Book (mrq)
0.90
Enterprise Value/Revenue
1.22
Enterprise Value/EBITDA
15.33
Financial Highlights
Profitability and Income Statement
Profit Margin
3.17%
Return on Assets (ttm)
2.99%
Return on Equity (ttm)
5.30%
Revenue (ttm)
19.49B
Net Income Avi to Common (ttm)
617.91M
Diluted EPS (ttm)
1.04
Balance Sheet and Cash Flow
Total Cash (mrq)
1.07B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Research Analysis: FMS
View MoreResearch Reports: FMS
View MoreFresenius Medical Care: Sticking to 2025 Outlook as Medtech Margins Meet Goal
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three quarters of sales while the balance is generated from medical technology products that enable dialysis treatments.
RatingPrice TargetMedical Services: MCOs Immune, but Tariffs May Cause Near-Term Stress at Providers and Suppliers
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three quarters of sales while the balance is generated from medical technology products that enable dialysis treatments.
RatingPrice TargetFresenius Economic Profit Margins Should Rise Along With Improvement in Both Operating Segments
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three quarters of sales while the balance is generated from medical technology products that enable dialysis treatments.
RatingPrice TargetFresenius Medical Care Earnings: Profits Keep Expanding on Transformation Initiatives
Fresenius Medical Care is the largest dialysis company in the world, treating over 300,000 patients from roughly 3,750 clinics across the globe as of mid-2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%.
RatingPrice Target